Floatz logo

ds-8201a

Residual Invasive Breast Cancer

Daiichi Sankyoantibody_drug_conjugatePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Residual Invasive Breast Cancer cohort.

Asset / SponsorPhaseRating
Trastuzumab Emtansine
Daiichi Sankyo
Phase 3B

Same molecule, other indications

ds-8201a is also rated in:

breast neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
HER2 positive breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →